Who
Helen Louise Collins
Chief Medical Officer
Company insider
Files Form 4 as: Chief Medical Officer, Enliven Therapeutics; Director, Kura Oncology; Director, IO Biotech; EVP and Chief Medical Officer, Five Prime Therapeutics.
In numbers
- Trades disclosed
- 168
- Buys
- 0
- Sells
- 14
- Bought
- $0
- Sold
- $11.5M
- Companies
- 4
- Companies where not an officer
- 2
- First trade
- 20 Mar 2017
- Last trade
- 19 Oct 2026
- Last filed
- 21 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 19 Oct 2026filed 21 Oct 2026 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Code M | $12K5,000 at $2.48 | filing |
| 19 Oct 2026filed 21 Oct 2026 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Sold | $192K5,000 at $38.47 | filing |
| 19 Oct 2026filed 21 Oct 2026 | ELVN Enliven Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,000 at $0.00 | filing |
| 17 Sep 2026filed 21 Sep 2026 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Code M | $12K5,000 at $2.48 | filing |
| 17 Sep 2026filed 21 Sep 2026 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Sold | $146K2,916 at $50.03 | filing |
| 17 Sep 2026filed 21 Sep 2026 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Sold | $94K1,844 at $50.71 | filing |
| 17 Sep 2026filed 21 Sep 2026 | ELVN Enliven Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,000 at $0.00 | filing |
| 17 Sep 2026filed 21 Sep 2026 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Sold | $12K240 at $51.48 | filing |
| 17 Sep 2026filed 21 Sep 2026 | ELVN Enliven Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,000 at $0.00 | filing |
| 17 Sep 2026filed 21 Sep 2026 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Code M | $12K5,000 at $2.48 | filing |
| 17 Sep 2026filed 21 Sep 2026 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Sold | $146K2,916 at $50.03 | filing |
| 17 Sep 2026filed 21 Sep 2026 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Sold | $94K1,844 at $50.71 | filing |
| 17 Sep 2026filed 21 Sep 2026 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Sold | $12K240 at $51.48 | filing |
| 17 Aug 2026filed 19 Aug 2026 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Code M | $12K5,000 at $2.48 | filing |
| 17 Aug 2026filed 19 Aug 2026 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Sold | $228K3,900 at $58.37 | filing |
| 17 Aug 2026filed 19 Aug 2026 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Sold | $65K1,100 at $59.35 | filing |
| 17 Aug 2026filed 19 Aug 2026 | ELVN Enliven Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,000 at $0.00 | filing |
| 17 Aug 2026filed 19 Aug 2026 | ELVN Enliven Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,000 at $0.00 | filing |
| 17 Aug 2026filed 19 Aug 2026 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Code M | $12K5,000 at $2.48 | filing |
| 17 Aug 2026filed 19 Aug 2026 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Sold | $228K3,900 at $58.37 | filing |
News
Enliven Therapeutics (NASDAQ:ELVN) Stock Price Expected to Rise, HC Wainwright Analyst SaysELVN · dailypolitical.com · 21 Oct 2026Enliven Therapeutics Appoints Kristine Ball to Board of Directors Ahead of Planned Phase 3 Trial Initiation this YearELVN · prnewswire.com · 14 Oct 2026
0 headlines in the last 90 days name Helen Louise Collins; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.